Chirag A Shah

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer
    Chirag Shah
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 99:564-70. 2005
  2. pmc Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125
    Chirag A Shah
    University of Washington, Seattle, WA 98195, USA
    Cancer Epidemiol Biomarkers Prev 18:1365-72. 2009
  3. pmc Factors affecting risk of mortality in women with vaginal cancer
    Chirag A Shah
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle, Washington 98195 6460, USA
    Obstet Gynecol 113:1038-45. 2009
  4. doi request reprint Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
    Chirag A Shah
    University of Washington Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Seattle, Washington 98195, USA
    Gynecol Oncol 109:215-9. 2008
  5. ncbi request reprint Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis
    Chirag Shah
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington Medical Center, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 103:1130-2. 2006
  6. doi request reprint Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
    Gynecol Oncol 116:340-4. 2010
  7. doi request reprint Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
    Gynecol Oncol 118:43-6. 2010
  8. doi request reprint An evaluation of cervical cancer in women age sixty and over
    Katrina V Fox
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Gynecol Oncol 109:53-8. 2008
  9. doi request reprint Pelvic exenteration in the age of modern chemoradiation
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 121:131-4. 2011
  10. doi request reprint Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases
    Pamela J Paley
    Pacific Gynecology Specialists Inc, Swedish Medical Center, Seattle, WA 98104, USA
    Am J Obstet Gynecol 204:551.e1-9. 2011

Detail Information

Publications11

  1. ncbi request reprint Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial cancer
    Chirag Shah
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 99:564-70. 2005
    ..To determine whether tumor size or morphology is predictive of extrauterine disease and/or recurrence risk in endometrial cancer and therefore guide decisions about the necessity of complete surgical staging and adjuvant therapy...
  2. pmc Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125
    Chirag A Shah
    University of Washington, Seattle, WA 98195, USA
    Cancer Epidemiol Biomarkers Prev 18:1365-72. 2009
    ..To evaluate the effect of ovarian cancer risk on the performance of the serum biomarkers mesothelin, human epididymis protein 4 (HE4), and CA125...
  3. pmc Factors affecting risk of mortality in women with vaginal cancer
    Chirag A Shah
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle, Washington 98195 6460, USA
    Obstet Gynecol 113:1038-45. 2009
    ..To estimate the current effect of demographics, pathology, and treatment on mortality among women with vaginal cancer...
  4. doi request reprint Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
    Chirag A Shah
    University of Washington Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Seattle, Washington 98195, USA
    Gynecol Oncol 109:215-9. 2008
    ..Forty percent of women with ovarian cancer have circulating free tumor DNA. We sought to determine if the tumor immune infiltrate varied based on tumor p53 mutation status or presence of circulating tumor DNA...
  5. ncbi request reprint Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis
    Chirag Shah
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington Medical Center, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 103:1130-2. 2006
    ..Malignant transformation of endometriosis is an infrequent complication of endometriosis. Extragonadal disease is uncommon...
  6. doi request reprint Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
    Gynecol Oncol 116:340-4. 2010
    ..We hypothesized that women treated with alternative IP chemotherapy strategies may have less toxicity and improved compliance...
  7. doi request reprint Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
    Gynecol Oncol 118:43-6. 2010
    ..Recent studies have suggested inferior outcomes for elderly women with ovarian cancer. Our goal was to evaluate neoadjuvant chemotherapy versus primary cytoreduction in elderly women...
  8. doi request reprint An evaluation of cervical cancer in women age sixty and over
    Katrina V Fox
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Gynecol Oncol 109:53-8. 2008
    ..To assess prior cervical cancer screening, stage at time of diagnosis and outcome in women sixty years of age and over with cervical cancer...
  9. doi request reprint Pelvic exenteration in the age of modern chemoradiation
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 121:131-4. 2011
    ..To examine outcomes after pelvic exenteration in women treated with modern chemoradiation and surgical techniques...
  10. doi request reprint Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases
    Pamela J Paley
    Pacific Gynecology Specialists Inc, Swedish Medical Center, Seattle, WA 98104, USA
    Am J Obstet Gynecol 204:551.e1-9. 2011
    ..We sought to examine outcomes in an expanding robotic surgery (RS) program...
  11. pmc Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma
    Tilley Jenkins Vogel
    Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
    Transl Oncol 5:247-51. 2012
    ..Angiogenesis is critical in neoplastic growth and metastasis. We sought to determine whether circulating neoplastic DNA results from alterations in the balance of angiogenesis activators and inhibitors...